Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Aug;126(2):310-315.
doi: 10.1097/AOG.0000000000000958.

Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial

Rosario D'Anna  1 , Antonino Di Benedetto, Angela Scilipoti, Angelo Santamaria, Maria Lieta Interdonato, Elisabetta Petrella, Isabella Neri, Basilio Pintaudi, Francesco Corrado, Fabio Facchinetti
Affiliations
Randomized Controlled Trial

Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial

Rosario D'Anna et al. Obstet Gynecol. 2015 Aug.

Abstract

Objective: To evaluate whether myo-inositol supplementation, an insulin sensitizer, reduces the rate of gestational diabetes mellitus (GDM) and lowers insulin resistance in obese pregnant women.

Methods: In an open-label, randomized trial, myo-inositol (2 g plus 200 micrograms folic acid twice a day) or placebo (200 micrograms folic acid twice a day) was administered from the first trimester to delivery in pregnant obese women (prepregnancy body mass index 30 or greater. We calculated that 101 women in each arm would be required to demonstrate a 65% GDM reduction in the myo-inositol group with a statistical power of 80% (α=0.05). The primary outcomes were the incidence of GDM and the change in insulin resistance from enrollment until the diagnostic oral glucose tolerance test.

Results: From January 2011 to April 2014, 220 pregnant women at 12-13 weeks of gestation were randomized at two Italian university hospitals, 110 to myo-inositol and 110 to placebo. Most characteristics were similar between groups. The GDM rate was significantly reduced in the myo-inositol group compared with the control group, 14.0% compared with 33.6%, respectively (P=.001; odds ratio 0.34, 95% confidence interval 0.17-0.68). Furthermore, women treated with myo-inositol showed a significantly greater reduction in the homeostasis model assessment of insulin resistance compared with the control group, -1.0±3.1 compared with 0.1±1.8 (P=.048).

Conclusion: Myo-inositol supplementation, started in the first trimester, in obese pregnant women seems to reduce the incidence in GDM through a reduction of insulin resistance.

Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01047982.

PubMed Disclaimer

References

    1. Gestational diabetes. ACOG Practice Bulletin No. 30. American College of Obstetricians and Gynecologists. Obstet Gynecol 2001;98:525–38.
    1. Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, et al.. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 2011;28:972–5.
    1. D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, et al.. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes. Diabetes Care 2013;36:854–7.
    1. Saltiel AR. Second messengers of insulin action. Diabetes Care 1990;13:244–56.
    1. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositol phosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8:127–36.

Publication types

MeSH terms

Associated data